Clinical Trials Logo

Recurrent clinical trials

View clinical trials related to Recurrent.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06314152 Recruiting - Chronic Pain Clinical Trials

3-point With 1-point Mesh Fixation in TAPP for Inguinal Hernia

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This study was designed to compare the outcome of 3 point with 1 point lightweight mesh fixation in TAPP surgery for patients with inguinal hernia. The main outcome include seroma, chronic pain, recurrence, et al.

NCT ID: NCT06164600 Recruiting - Clinical trials for Urinary Tract Infections

Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

Prebiotics as bovine colostrum are considered as a valuable supplement in the prevention of upper respiratory tract infections, gastrointestinal tract infections and neonatal sepsis. It contains many bioactive substances, such as immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, and other growth factors.There is a lack of research on the use of prebiotics for prophylaxis against recurrent urinary tract infection (UTI) in children.In this era of increasing bacterial resistance to antimicrobial therapy, bovine colostrum can offer an approach for prophylaxis against UTI in these patients.We aim at this trial to evaluate the efficacy and safety of bovine colostrum as a prebiotic for prophylaxis against recurrent urinary tract infection in children.

NCT ID: NCT06007937 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Start date: August 17, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.

NCT ID: NCT05772390 Recruiting - Breast Cancer Clinical Trials

Partial Breast Re-irradiation in Women in Women With Locally Recurrent Breast Cancer Previously Treated With Conservative Surgery and Whole Breast Irradiation

PBReI
Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

A prospective study of partial breast re-irradiation in patients with local recurrence of breast cancer

NCT ID: NCT01151722 Recruiting - Hemorrhage Clinical Trials

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage

ABeVi
Start date: December 2009
Phase: Phase 2
Study type: Interventional

Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. There have been efforts to lower the incidence of postoperative vitreous hemorrhage such as preoperative bevacizumab injection. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. Recently there have been reports showing that preoperative bevacizumab injection could reduce intraoperative bleeding from abnormal vessels and could make surgery easier and more successful. Our hypothesis is that intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery. We started the prospective randomized comparative study to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without any adjuvant drug.

NCT ID: NCT00510107 Recruiting - Stomach Neoplasm Clinical Trials

Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Start date: July 2007
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.

NCT ID: NCT00364962 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients

Start date: April 2006
Phase: N/A
Study type: Observational

Investigate the treatment result of KTP laser nasopharyngectomy in recurrent NPC patients